Effect of l-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: Protocol for a randomised, controlled trial

BMJ Open

Volumn 4, Issue 12, 2014, Pages

  Shakoor, Amarah ^a   Zahoor, Maaman ^a   Sadaf, Alina ^a   Alvi, Najveen ^a   Fadoo, Zehra ^a   Rizvi, Arjumand ^a   Quadri, Farheen ^a   Tipoo, Fateh Ali ^b   Khurshid, Mohammad ^b   Sajjad, Zaffar ^a   Colan, Steven ^c   Hasan, Babar S ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CHELATING AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; BONE DYSPLASIA; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CYANOSIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPOTENSION; INFUSION PUMP; INJECTION SITE REACTION; IRON CHELATION; IRON OVERLOAD; LEUKOPENIA; LIVER DYSFUNCTION; MOTOR NEUROPATHY; MUSCLE SPASM; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERIPHERAL EDEMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SENSORY NEUROPATHY; SHOCK; SINUS BRADYCARDIA; SOMNOLENCE; TACHYCARDIA; THALASSEMIA; THALASSEMIA MAJOR; THROMBOCYTOPENIA; URTICARIA; CARDIOMYOPATHIES; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART; HEART MUSCLE; HEART STROKE VOLUME; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CARDIOMYOPATHIES; CHELATING AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; IRON; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING, CINE; MALE; MYOCARDIUM; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; THALASSEMIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927163410     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005360     Document Type: Article

References (37)

1. Khateeb B, Moatter T, Shaghil AM, et al. Genetic diversity of beta-thalassemia mutations in Pakistani population. J Pak Med Assoc 2000;50:293-6.
2. Rahman M, Lodhi Y. Prospects and future of conservative management of beta thalassemia major in a developing country. Pak J Med Sci 2004;20:105-12.
3. Arif F, Fayyaz J, Hamid A. Awareness among parents of children with thalassemia major. J Pak Med Assoc 2008;58:621-4.
4. Yang T, Brittenham GM, Dong WQ, et al. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003;142:332-40.
5. Yang T, Dong WQ, Kuryshev YA, et al. Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med 2002;140:263-71.
6. Wood JC, Otto-Duessel M, Gonzalez I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006;148:272-80.
7. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346-9.
8. Gujja P, Rosing DR, Tripodi DJ, et al . Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010;56:1001-12.
9. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-30.
10. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40-7.
11. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
12. Chern JP, Su S, Lin KH, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer 2007;48:550-4.
13. Chattipakorn N, Kumfu S, Fucharoen S, et al. Calcium channels and iron uptake into the heart. World J Cardiol 2011;3:215-18.
14. Oudit GY, Trivieri MG, Khaper N, et al. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl) 2006;84:349-64.
15. Tsushima RG, Wickenden AD, Bouchard RA, et al. Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 1999;84:1302-9.
16. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-94.
17. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-3.
18. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341: 99-109.
19. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115:2364-71.
20. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with beta-thalassemia major. Haematologica 2012;97: 842-8.
21. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2 over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica 2011;96:48-54.
22. Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson 2013;15:1.
23. Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011;47:166-75.
24. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
25. Veríssimo MP, Loggetto SR, Fabron Junior A, et al. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. Rev Bras Hematol Hemoter 2013;35:428-34.
26. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2 cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33-9.
27. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
28. Khouri SJ, Maly GT, Suh DD, et al. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-7.
29. Fernandes JL, Sampaio EF, Fertrin K, et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med 2013;126:834-7.
30. Sauerbrey-Wullkopf N, Kupper W. [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. Herz 2001;26:149-56.
31. Buck ML. Amlodipine use in pediatric hypertension. Pediatr Pharmacother July 2003;9:7. http://www.medscape.com/viewarticle/ 460500
32. Mavrogeni S, Pepe A, Lombardi M. Evaluation of myocardial iron overload using cardiovascular magnetic resonance imaging. Hellenic J Cardiol 2011;52:385-90.
33. Westwood MA Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassaemia major patients with normal myocardial iron. J Magn Reson Imaging 2007;25:1147-51.
34. He T, Gatehouse PD, Kirk P, et al. Myocardial T2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn Reson Med 2008;60:350-6.
35. Bonny JM, Zanca M, Boire JY, et al. T2 maximum likelihood estimation from multiple spin-echo magnitude images. Magn Reson Med 1996;36:287-93.
36. Carpenter JP, He T, Kirk P, et al. On T2 magnetic resonance and cardiac iron. Circulation 2011;123:1519-28.
37. Wyatt HL, Meerbaum S, Heng MK, et al. Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 1980;100(6 Pt 1):821-8.